Features of the course and eradication of multidrug-resistant Pseudomonas aeruginosa infection in cystic fibrosis: clinical case-Reference-Cited by-同舟云学术

Features of the course and eradication of multidrug-resistant Pseudomonas aeruginosa infection in cystic fibrosis: clinical case

Published:2021-10-30 Issue:16 Volume: Page:166-173
ISSN:2658-5790
Container-title:Meditsinskiy sovet = Medical Council
language:
Short-container-title:Medicinskij sovet

Author:

Kondratyeva E. I.¹^ORCID,Loshkova E. V.²^ORCID,Nikolaeva E. D.¹^ORCID,Khachiyan M. M.³^ORCID,Yankina G. N.²^ORCID

Affiliation:

1. Academician Bochkov Medical Genetic Research Center; Moscow Region Scientific Research Clinical Institute

2. Siberian State Medical University

3. Children’s Regional Clinical Hospital

Abstract

Chronic lung infection caused by Pseudomonas aeruginosa reduces respiratory function and life expectancy in people with cystic fibrosis. Up to 2/3 of hospitalized patients, have antibiotic-resistant strains of Pseudomonas aeruginosa, which presents significant difficulties in prescribing eradication antibiotic therapy, which in some cases is aggravated by undesirable side effects of antimicrobial chemotherapy. The nutritional status of patients with cystic fibrosis is directly related to the activity of chronic pulmonary infection and the frequency of pulmonary exacerbations. A clinical example discusses the tactics of prescribing an alternative inhaled antibiotic aztreonam lysine (Cayston (Aztreonam lysine), Gilead Sciences Inc.) active against carbapenemases, including metallobetalactamases, in a patient with multidrug-resistant Pseudomonas aeruginosa. The clinical case demonstrates the successful eradication of the multidrug-resistant biotypes of Pseudomonas aeruginosa, and, as a consequence, the improvement of respiratory function and nutritional status, including the normalization of the 25(OH)D level in the patient.

Publisher

Remedium, Ltd.

Subject

General Medicine

Reference25 articles.

1. Kondratieva E.I., Kashirskaya N.Yu., Kapranov N.I. National Consensus “Cystic Fibrosis: Definition, Diagnostic Criteria, Therapy”: Draft. 2nd ed. Moscow: Kompaniya BORGES; 2018. 356 p. (In Russ.) Available at: https://mukoviscidoz.org/doc/konsensus/2019/konsensus-2019-bez-rentgenogramm.pdf.

2. Castellani C., Duff A.J.A., Bell S.C., Heijerman H.G.M., Munck A., Ratjen F. et al. ECFS Best Practice Guidelines: the 2018 Revision. J Cyst Fibros. 2018;17(2):153–178. https://doi.org/10.1016/j.jcf.2018.02.006.

3. Zolin A., Orenti A., Naehrlich L., Jung A., van Rens J., Fox A. et al. ECFS Patient Registry. Annual Data Report. 2018 Data. Karup: European Cystic Fibrosis Society; 2020. 149 p. Available at: https://www.ecfs.eu/sites/default/files/general-content-files/working-groups/ecfs-patient-registry/ECFSPR_Report_2018_v1.4.pdf.

4. Marshall B., Faro A., Elbert A., Fink A., Cho J., Ostrenga J. et al. Cystic Fibrosis Foundation. Patient Registry. 2019 Annual Data Report. Bethesda: Cystic Fibrosis Foundation; 2020. 85 p. Available at: https://www.cff.org/Research/Researcher-Resources/Patient-Registry/2019-Patient-RegistryAnnual-Data-Report.pdf.

5. Hatziagorou E., Orenti A., Drevinek P., Kashirskaya N., Mei-Zahav M., De Boeck K. Changing Epidemiology of the Respiratory Bacteriology of Patients with Cystic Fibrosis-Data from the European Cystic Fibrosis Society Patient Registry. J Cyst Fibros. 2020;19(3):376–383. https://doi.org/10.1016/j.jcf.2019.08.006.